REGENXBIO Inc. highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal diseases. "2026 is set to be a transformative year for REGENXBIO, ...
Company now expects to complete enrollment of 150 patients in Q2 2026, with a Phase 3 data readout in mid-2027; Rolling NDA ...
This brief exchange captured, in microcosm, the rhythm of life alongside serious illness. Pamela was in the hospital with her ...
Exelixis, Inc. today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis ...
Mary-Margaret Murray and 39 other East Tennessee young professionals were honored in Knoxville as they joined Knox News' 40 Under 40 Class of 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback